 | |
| Company type | Public |
|---|---|
| Headquarters | Rancho Cucamonga, California, United States |
Key people |
|
| Revenue |  US$ 644.4 million (2023) |
| US$ 196.9 million (2023) | |
| US$ 137.5 million (2023) | |
| Total assets | US$ 741.9 million (2022) |
| Total equity | US$ 528.6 million (2022) |
Number of employees | 1,615 |
| Website | Amphastar.com |
| Footnotes / references [1][2][3] | |
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company.[4] It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.[5]
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic.[6] In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.[6]
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.[7]
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.[8][9]
See also[edit]
References[edit]
- ^ "U.S. SEC: Form 10-K, Amphstar Pharmaceuticals, Inc". U.S. Securities and Exchange Commission. Retrieved July 31, 2023.
- ^ "Amphastar Pharmaceuticals Inc". Bloomberg. Retrieved 2024-03-19.
- ^ "Amphastar Pharmaceuticals, Inc. (AMPH) Income Statement - Yahoo Finance". finance.yahoo.com. Retrieved 2024-03-19.
- ^ "Amphastar Pharmaceuticals, Inc. (AMPH)". NASDAQ.com. NASDAQ OMX Group. Retrieved 3 January 2016.
- ^ "Profile:Amphastar Pharmaceuticals Inc (AMPH.O)". Reuters.
- ^ a b Arsalan, Arif (February 21, 2017). "After steering through a controversy over soaring price of naloxone, FDA rejects Amphastar's intranasal version". Endpoints.
- ^ Raymond, Nate (June 19, 2019). "Momenta, Amphastar settle generic Lovenox drug patent case". Reuters. Retrieved March 14, 2024.
- ^ "Eli Lilly Divests Low Blood Sugar Drug Baqsimi To Amphastar For $500M Cash". Yahoo Finance. 24 April 2023. Retrieved 2023-04-26.
- ^ "Amphastar buys Baqsimi to build out specialty med offering". www.thepharmaletter.com. Retrieved 2023-04-26.
External links[edit]
- Official website
- Business data for Amphstar Pharmaceuticals, Inc.: